keyword
MENU ▼
Read by QxMD icon Read
search

Nilotinib

keyword
https://www.readbyqxmd.com/read/28319280/nilotinib-induced-panniculitis-in-a-patient-with-chronic-myelogenous-leukemia
#1
Naomi Kitayama, Atsushi Otsuka, Chiaki Hamamoto, Yo Kaku, Hiroshi Shiragami, Yoshiyuki Okumura, Kaoru Tsujioka
Nilotinib is a second-generation tyrosine kinase inhibitors (TKIs) developed to target the bcr-abl protein for the treatment of chronic myelogenous leukemia (CML). [1] Nilotinib has been described as a well-tolerated drug. The most common non-hematologic side effects are skin rash, pruritus, headache, nausea, and fatigue. Cases of panniculitis induced by the other bcr-able TKIs such as imatinib, dasatinib and ponatinib were rarely described in the literature.[2-5] However, a case of panniculitis induced by nilotinib has not been reported...
March 20, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28316033/cardiovascular-complications-of-targeted-therapies-for-chronic-myeloid-leukemia
#2
REVIEW
Rongras Damrongwatanasuk, Michael G Fradley
The development of tyrosine kinase inhibitors (TKIs) dramatically changed the treatment landscape for many different cancers including chronic myeloid leukemia (CML). With the introduction of imatinib, the first TKI developed and approved to effectively treat CML, patient survival has increased dramatically and, in some cases, this fatal cancer can be managed as a chronic disease. Since the approval of imatinib in 2002, four additional TKIs have been developed to treat this disease including the second-generation TKIs nilotinib, dasatinib, and bosutinib and the third-generation TKI ponatinib...
April 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28300891/lichen-planopilaris-like-eruption-during-treatment-with-tyrosine-kinase-inhibitor-nilotinib
#3
Juliana Ribeiro Leitão, Neusa Yuriko Sakai Valente, Priscila Kakizaki, Isis Suga Veronez, Mario Cezar Pires
Tyrosine kinase inhibitors are effective as a target therapy for malignant neoplasms. Imatinib was the first tyrosine kinase inhibitor used. After its introduction, several other drugs have appeared with a similar mechanism of action, but less prone to causing resistance. Even though these drugs are selective, their toxicity does not exclusively target cancer cells, and skin toxicity is the most common non-hematologic adverse effect. We report an eruption similar to lichen planopilaris that developed during therapy with nilotinib, a second generation tyrosine kinase inhibitor, in a patient with chronic myeloid leukemia resistant to imatinib...
September 2016: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28298564/proteomic-analysis-of-sera-from-individuals-with-diffuse-cutaneous-systemic-sclerosis-reveals-a-multianalyte-signature-associated-with-clinical-improvement-during-imatinib-mesylate-treatment
#4
D James Haddon, Hannah E Wand, Justin A Jarrell, Robert F Spiera, Paul J Utz, Jessica K Gordon, Lorinda S Chung
OBJECTIVE: Imatinib has been investigated for the treatment of systemic sclerosis (SSc) because of its ability to inhibit the platelet-derived growth factor receptor and transforming growth factor-β signaling pathways, which have been implicated in SSc pathogenesis. In a 12-month open-label clinical trial assessing the safety and efficacy of imatinib in the treatment of diffuse cutaneous SSc (dcSSc), significant improvements in skin thickening were observed. Here, we report our analysis of sera collected during the clinical trial...
March 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28283715/label-free-visualization-of-nilotinib-functionalized-gold-nanoparticles-within-single-mammalian-cells-by-c60-sims-imaging
#5
Anna N Bloom, Hua Tian, Christian Schoen, Nicholas Winograd
Obtaining a comprehensive grasp of the behavior and interaction of pharmaceutical compounds within single cells provides some of the fundamental details necessary for more effective drug development. In particular, the changes ensuing in the carrier, drug, and host environment in targeted drug therapy applications must be explored in greater detail, as these are still not well understood. Here, nilotinib-functionalized gold nanoparticles are examined within single mammalian cells with use of imaging cluster secondary ion mass spectrometry in a model study designed to enhance our understanding of what occurs to these particles once that have been internalized...
March 10, 2017: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/28283298/the-efficacy-of-generic-imatinib-as-first-and-second-line-therapy-3-year-follow-up-of-patients-with-chronic-myeloid-leukemia
#6
Erna Islamagic, Azra Hasic, Sabira Kurtovic, Emina Suljovic Hadzimesic, Lejla Mehinovic, Mirza Kozaric, Amina Kurtovic-Kozaric
INTRODUCTION: Generics of imatinib mesylate, the first tyrosine kinase inhibitor targeting the BCR-ABL1 fusion protein, have recently been approved in many countries as the alternative, low-cost forms for the treatment of patients with chronic myeloid leukemia (CML). The aim of this study was to evaluate the long-term clinical outcomes of patients with CML receiving first-line and second-line generic imatinib in Bosnia and Herzegovina. PATIENTS AND METHODS: This was a multicenter retrospective cohort study of patients (n = 41) treated with generic imatinib in Bosnia between September 1, 2013 and August 5, 2016...
February 16, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28282612/imatinib-induces-sustained-progression-arrest-in-recist-progressive-desmoid-tumours-final-results-of-a-phase-ii-study-of-the-german-interdisciplinary-sarcoma-group-gisg
#7
Bernd Kasper, Viktor Gruenwald, Peter Reichardt, Sebastian Bauer, Geraldine Rauch, Ronald Limprecht, Michaela Sommer, Antonia Dimitrakopoulou-Strauss, Lothar Pilz, Florian Haller, Peter Hohenberger
BACKGROUND: Desmoid tumours describe a rare monoclonal, fibroblastic proliferation characterised by an often unpredictable clinical course. Surgery is one therapeutic option for progressing patients, except if mutilating and associated with considerable function loss. Different systemic treatment approaches have been investigated and promising results could be demonstrated using imatinib. PATIENTS AND METHODS: We initiated a phase II trial within the German Interdisciplinary Sarcoma Group (GISG) evaluating imatinib to induce progression arrest in desmoid tumour patients being Response Evaluation Criteria in Solid Tumours (RECIST) progressive, not amenable to surgical resection with R0 intent or accompanied by unacceptable function loss (NCT01137916)...
March 7, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28271998/myeloid-sarcoma-as-the-first-sign-of-progression-of-chronic-myeloid-leukemia-in-medullary-chronic-phase-experience-from-a-tertiary-cancer-centre-in-southern-india
#8
(no author information available yet)
INTRODUCTION: Myeloid sarcoma (MS) in chronic myeloid leukemia (CML) is a rare entity which is suggestive of advanced phase of the disease and poorer outcomes. There is little data in literature available regarding its presentation in medullary chronic phase (CP) as well as outcomes in the era of tyrosine kinase inhibitors (TKI) and needs to be carefully evaluated as it can present the first sign of progressive disease before haematological progression. METHODS: We identified cases of MS presenting with medullary CML-CP from January 2002 to December 2015...
January 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28255764/erratum-to-pregnancy-outcome-among-partners-of-male-patients-receiving-imatinib-dasatinib-or-nilotinib-in-chronic-myeloid-leukemia-reports-collected-by-the-french-network-pharmacovigilance-centers
#9
Patrick Carlier, Maritza Markarian, Nathalie Bernard, Laurence Lagarce, Anne Dautriche, Johanna Béné, Nathalie Fouilhe Sam-Lai, Pirayeh Eftekhari
No abstract text is available yet for this article.
April 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28224300/nilotinib-first-line-therapy-in-patients-with-philadelphia-chromosome-negative-bcr-abl-positive-chronic-myeloid-leukemia-in-chronic-phase-enest1st-sub-analysis
#10
Andreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, Ljubomir Petrov, Jeroen J W M Janssen, Nicholas C P Cross, Delphine Rea, Fausto Castagnetti, Andrzej Hellmann, Gianantonio Rosti, Norbert Gattermann, Maria Liz Paciello Coronel, Maria Asuncion Echeveste Gutierrez, Valentin Garcia-Gutierrez, Beatrice Vincenzi, Luca Dezzani, Francis J Giles
PURPOSE: The ENEST1st sub-analysis presents data based on Philadelphia chromosome (Ph) status, i.e., Ph+ and Ph-/BCR-ABL1 + chronic myeloid leukemia. METHODS: Patients received nilotinib 300 mg twice daily, up to 24 months. RESULTS: At screening, 983 patients were identified as Ph+ and 30 patients as Ph-/BCR-ABL + based on cytogenetic and RT-PCR assessment; 76 patients had unknown karyotype (excluded from this sub-analysis). In the Ph-/BCR-ABL1 + subgroup, no additional chromosomal aberrations were reported...
February 21, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28218239/treatment-free-remission-following-frontline-nilotinib-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-results-from-the-enestfreedom-study
#11
A Hochhaus, T Masszi, F J Giles, J P Radich, D M Ross, M T G Casares, A Hellmann, J Stentoft, E Conneally, V García-Gutiérrez, N Gattermann, W Wiktor-Jedrzejczak, P D le Coutre, B Martino, S Saussele, H D Menssen, W Deng, N Krunic, V Bedoucha, G Saglio
The single-arm, phase 2 ENESTfreedom trial (ClinicalTrials.gov, NCT01784068) assessed the potential for treatment-free remission (TFR; ie, the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) with MR(4.5) (BCR-ABL1⩽0.0032% on the International Scale; BCR-ABL1(IS)) and ⩾2 years of frontline nilotinib therapy were enrolled. Patients with sustained deep molecular response during the 1-year nilotinib consolidation phase were eligible to stop treatment and enter the TFR phase...
February 20, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28199182/one-reporter-for-in-cell-activity-profiling-of-majority-of-protein-kinase-oncogenes
#12
Iva Gudernova, Silvie Foldynova-Trantirkova, Barbora El Ghannamova, Bohumil Fafilek, Miroslav Varecha, Lukas Balek, Eva Hruba, Lucie Jonatova, Iva Jelinkova, Michaela Kunova Bosakova, Lukas Trantirek, Jiri Mayer, Pavel Krejci
In-cell profiling enables the evaluation of receptor tyrosine activity in a complex environment of regulatory networks that affect signal initiation, propagation and feedback. We used FGF-receptor signaling to identify EGR1 as a locus that strongly responds to the activation of a majority of the recognized protein kinase oncogenes, including 30 receptor tyrosine kinases and 154 of their disease-associated mutants. The EGR1 promoter was engineered to enhance trans-activation capacity and optimized for simple screening assays with luciferase or fluorescent reporters...
February 15, 2017: ELife
https://www.readbyqxmd.com/read/28191543/the-third-time-chronic-myeloid-leukemia-in-lymphoblastic-crisis-with-abl1-kinase-mutation-induced-by-decitabine-dexamethason-combined-with-nilotinib-and-dasatinib
#13
Suli Wang, Chun Qiao, Yu Zhu, Wenyi Shen, Guangsheng He, Jianyong Li
Blast crisis (BC) is the major remaining challenge in the management of chronic myeloid leukemia (CML). The prognosis of the BC patient who carries ABL kinase mutation is very poor. One patient, with lymphoid CML-BC third time, was detected with T315A/F359I/M244V compound mutation by direct sequencing after treatment with tyrosine kinase inhibitions three years. The patient was treated with decitabine, dexamethasone, in combination with nilotinib and dasatinib. Then this patient received a complete hematologic response and cytogenetic response after two cycles of treatment...
December 1, 2016: Journal of Translational Internal Medicine
https://www.readbyqxmd.com/read/28190859/renal-artery-stenosis-following-nilotinib-administration-in-a-patient-with-chronic-myelogenous-leukemia
#14
Mayumi Hatsuse, Yuka Daikoku, Yuta Tamoto, Masahiro Uehara, Takashi Kitani, Keiichi Tamagaki, Shin-Ichi Fuchida, Akira Okano, Satoshi Murakami, Chihiro Shimazaki
A 63-year-old male was diagnosed as having chronic phase CML in 2001. He obtained a major molecular response with imatinib (IM). In 2012, amulodipin was started for hypertension. In January 2013, IM was switched to nilotinib (NIL) in a clinical trial, and in February 2015, NIL was discontinued because MR(4.5) had been maintained for two years. One month later, he was admitted to our hospital because of headache and high blood pressure (194/108 mmHg). His urine test showed protein 3+ and occult blood 2+. His eGFR rapidly deteriorated from 45...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28185798/quality-of-life-and-adherence-to-therapy-in-patients-with-chronic-myeloid-leukemia-treated-with-nilotinib-as-a-second-line-therapy-a%C3%A2-multicenter-prospective-observational-study
#15
Tomasz Sacha, Joanna Góra-Tybor, Ewa Wąsak-Szulkowska, Sławomira Kyrcz-Krzemień, Ewa Mędraś, Rafał Becht, Grażyna Bober, Aneta Kotowska, Joanna Wącław, Andrzej Hellmann
INTRODUCTION: The aim of this study was to evaluate quality of life (QOL) and adherence to the therapy in patients with chronic myeloid leukemia in chronic phase treated with nilotinib as second-line therapy. PATIENTS AND METHODS: A multicenter, prospective, observational trial with 6 time points was conducted; 177 patients were recruited in 23 centers in Poland who were treated with nilotinib as second-line therapy because of the ineffectiveness or intolerance of their previous therapy...
January 10, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28135648/current-approach-to-the-treatment-of-chronic-myeloid-leukaemia
#16
REVIEW
Ivan Pasic, Jeffrey H Lipton
Of all the cancers, chronic myeloid leukaemia (CML) has witnessed the most rapid evolution of the therapeutic milieu in recent decades. The introduction of tyrosine kinase inhibitors (TKIs) as a therapeutic option has profoundly changed patient experience and outcome. The availability of multiple new highly effective therapies has increasingly underscored the importance of a good understanding of the underlying pathophysiological basis in CML, as well as patient-specific factors in choosing the right treatment for every individual...
January 11, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28135325/early-bcr-abl1-transcript-decline-after-1-month-of-tyrosine-kinase-inhibitor-therapy-as-an-indicator-for-treatment-response-in-chronic-myeloid-leukemia
#17
Mohamed El Missiry, Henrik Hjorth-Hansen, Johan Richter, Ulla Olson-Strömberg, Leif Stenke, Kimmo Porkka, Anna Kreutzman, Satu Mustjoki
In chronic myeloid leukemia (CML), early treatment prediction is important to identify patients with inferior overall outcomes. We examined the feasibility of using reductions in BCR-ABL1 transcript levels after 1 month of tyrosine kinase inhibitor (TKI) treatment to predict therapy response. Fifty-two first-line TKI-treated CML patients were included (imatinib n = 26, dasatinib n = 21, nilotinib n = 5), and BCR-ABL1 transcript levels were measured at diagnosis (dg) and 1, 3, 6, 12, 18, 24, and 36 months. The fold change of the BCR-ABL1 transcripts at 1 month compared to initial BCR-ABL1 transcript levels was used to indicate early therapy response...
2017: PloS One
https://www.readbyqxmd.com/read/28125915/modulation-of-d-galactosamine-lipopolysacharride-induced-fulminant-hepatic-failure-by-nilotinib
#18
D S El-Agamy, A M Shebl, A A Shaaban
This investigation was undertaken to test the effect of nilotinib against d-galactosamine (GalN) and lipopolysaccharide (LPS)-induced fulminant hepatic failure (FHF). Male Swiss albino mice were orally treated with nilotinib for 3 days prior to GalN/LPS challenge. The results revealed that administration of GalN/LPS caused elevation in the mortality rate. GalN/LPS-induced severe hepatic injury was manifested by increased serum transaminases and alkaline phosphatase (ALP) levels as well as histopathological hepatic necrosis and inflammation...
January 1, 2017: Human & Experimental Toxicology
https://www.readbyqxmd.com/read/28121203/chronic-myeloid-leukemia-with-a-novel-e8a1-bcr-abl1-fusion-rapid-molecular-response-with-nilotinib
#19
Mireille Crampe, Fatima Shakkak, Johanna Kelly, Andrew Hodgson, Stephen E Langabeer
No abstract text is available yet for this article.
January 25, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28117336/cd5-molecule-like-and-transthyretin-as-putative-biomarkers-of-chronic-myeloid-leukemia-an-insight-from-the-proteomic-analysis-of-human-plasma
#20
Iram Fatima, Saima Sadaf, Syed Ghulam Musharraf, Naghma Hashmi, Muhammad Waheed Akhtar
Better and sensitive biomarkers are needed to help understand the mechanism of disease onset, progression, prognosis and monitoring of the therapeutic response. Aim of this study was to identify the candidate circulating markers of chronic-phase chronic myeloid leukemia (CP-CML) manifestations, having potential to develop into predictive- or monitoring-biomarkers. A proteomic approach, two-dimensional gel electrophoresis in conjunction with mass spectrometry (2DE-MS), was employed for this purpose. Based on the spot intensity measurements, six proteins were found to be consistently dysregulated in CP-CML subjects compared to the healthy controls [false discovery rate (FDR) threshold ≤0...
January 24, 2017: Scientific Reports
keyword
keyword
20141
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"